The governance function and the execution function are not the same. Confusing them is costing portfolios more than most investors realise and the gap is widening in the age of AI.
A portfolio company misses its second consecutive quarter. The board convenes. Strategy gets reviewed, leadership gets scrutinised, financial controls get tightened. What rarely happens: anyone in that room diagnosing why the sales motion is broken, whether the ICP has drifted from the customer the team is actually selling to, or whether the VP of Sales peaked six months ago and nobody had the conversation. This is not a criticism of boards.
Boards are exceptional at what they are designed to do; strategy, financial oversight, network leverage, governance. But GTM execution diagnosis is not a governance skill. It is an operator skill. And confusing the two is one of the most consistent and costly blind spots in private equity and venture portfolio management.
The Board Sees the Miss. It Rarely Sees the Cause.
KPMG’s Private Company Board Effectiveness Survey found that 72% of portfolio company directors identified building forward-looking board agendas as the area needing the most improvement more than any other governance category. The challenge is not ambition. It is that boards are structurally positioned to review what has happened, not to diagnose why commercial execution is failing in real time.
Gartner’s research on commercial performance adds a sharper edge: between 2022 and 2024, sales organisations underwent an average of four major changes. Nearly two-thirds of sales leaders struggle to adapt their strategic plans to sudden change. Yet the board typically sees this as a leadership problem to be resolved through replacement, not as a GTM motion problem requiring operator-level diagnosis.
And Gartner’s 2025 CSO Leadership research shows that 80% of key commercial activities are missing meaningful contributions from either sales or marketing. When organisations bridge that gap, they are 2.3 times more likely to achieve strong commercial growth. Boards rarely have the visibility or the operator experience to see where those contributions are missing.
What Boards Cannot See From the Boardroom
The GTM failure modes that cost portfolios the most are almost never visible at board level until the damage is done. Here is what consistently goes undiagnosed:
- • A VP of Sales who has maxed out their capability and is managing down rather than building forward. The board sees a tenured leader with relationships. Operators see a team that has stopped growing.
- • An ICP that has shifted since the last round but messaging and targeting that has not. The board sees a pipeline coverage problem. Operators see a positioning problem.
- • A sales motion that was never documented and cannot be replicated by new hires. The board sees underperforming reps. Operators see a process that only the founder can execute.
- • AI-empowered buyers who are already 80% through their purchase decision before a sales conversation starts and a GTM motion built entirely for a world where that was not true.
PwC’s 2025 Annual Corporate Directors Survey found that 55% of directors believe at least one board colleague should be replaced — the highest proportion ever recorded. Directors know something is not working. They are just diagnosing it at the wrong level.
AI Is Widening the Gap Boards Cannot See.
The GTM execution gap that boards miss has always existed. AI has made it more consequential. Gartner projects that by 2028, 60% of B2B seller work will be executed through generative AI sales technologies. Portfolio companies running outdated GTM motions are not just underperforming — they are falling further behind every quarter as competitors deploy AI against the same buyers. This is not a technology decision a board can make. It is an execution decision that requires someone who understands what a modern, AI-enabled GTM motion actually looks like in practice.
How to Close the Gap Without Restructuring the Board
The solution is not to make boards into GTM operators. It is to stop expecting them to be. Here is what closes the gap:
1. Separate the governance review from the execution review.
Board meetings should review financial performance and strategic alignment. GTM execution reviews pipeline integrity, ICP validity, sales motion quality, leadership capability require a different cadence, different questions, and different expertise.
2. Bring in operator-level GTM expertise at the portfolio level.
The firms protecting portfolio value most effectively are not relying on board members to diagnose commercial execution. They are pairing governance oversight with operator-led GTM review people who have built and scaled revenue motions at the stage the company is in, not people who have advised on them from the boardroom.
3. Build GTM health into quarterly portfolio reviews.
Win rate by segment, sales cycle trend, rep productivity per tenure band, and ICP match rate against closed-won deals. These are the metrics that show a GTM motion breaking down three to six months before it shows up in revenue. They belong in every portfolio review not only in the post-mortem.
Governance Protects the Investment. Execution Grows It.
The board is not the problem. The assumption that governance oversight is sufficient to protect commercial performance is the problem. The most valuable thing an investor can do for a portfolio company is not just to hold leadership accountable in the boardroom, but to ensure there is operator-level execution expertise sitting alongside governance at every stage of growth.
Execution risk does not wait for the next board meeting to get worse.
